Oxytocin

Oxytocin is an endogenous cyclic nonapeptide hormone and is approved in multiple named jurisdictions for product-specific pharmaceutical (Pitocin, Syntocinon) for obstetric use — labour induction/augmentation and control of postpartum haemorrhage. It is on the WHO Model List of Essential Medicines. In obstetric settings it carries important warnings about uterine hyperstimulation, water intoxication, and is not indicated for elective induction. Off-label use for neuropsychiatric conditions (social cognition, autism) has failed to show benefit in large RCTs.

Oxytocin is a full agonist at the oxytocin receptor (OTR), a rhodopsin-type GPCR. Activation triggers Gq/PLC → IP₃ → intracellular Ca²⁺ release from stores plus store-operated and voltage-operated Ca²⁺ entry, increasing sodium permeability of uterine myofibrils and causing smooth muscle contraction. Uterine sensitivity to oxytocin increases with gestational age. Oxytocin also triggers milk ejection by contracting mammary myoepithelial cells. The mechanism is well-characterised and high confidence.

Approved labeled regimen

The label summary below is product-, indication-, and jurisdiction-specific; consult the full current label and a licensed clinician/pharmacist.

FDA-approved regimens (Pitocin):

• Labour induction/augmentation: IV infusion, initial 0.5–2 mU/min, titrated every 15–40 min; maximum typically 20 mU/min

• Postpartum haemorrhage: 10–40 U in IV infusion or 10 U IM after placental delivery

• Incomplete/inevitable abortion: IV infusion 10 U in 500 mL at 10–20 mU/min

Studied regimens (not recommendations)

Intranasal oxytocin has been studied for off-label psychiatric indications at doses of 8–40 IU per dose, with no established efficacy.

What is not established

• Safe or effective dose for any non-obstetric indication

• Long-term safety of chronic intranasal use

• Optimal regimen for postpartum haemorrhage in resource-limited settings

Established label risks

FDA boxed warning: Not indicated for elective induction of labour. Available data are inadequate to evaluate benefits-to-risks for elective induction.

Major warnings:

• Uterine hyperstimulation → fetal distress, hypoxia, uterine rupture

• Water intoxication (antidiuretic effect with high-dose prolonged infusion)

• Maternal hypotension (rapid IV bolus)

• Fetal bradycardia, hyperbilirubinemia, neonatal jaundice

Contraindications: Significant cephalopelvic disproportion, unfavourable fetal positions, fetal distress, hyperactive uterus, conditions contraindicating vaginal delivery (invasive cervical carcinoma, active herpes genitalis, total placenta previa, vasa previa, cord prolapse), hypersensitivity.

Human-study signals

Well-characterised in obstetric populations. For intranasal off-label use in psychiatric conditions, the SOARS-B trial and other large RCTs have not shown safety concerns distinct from placebo.

Unknowns and product-quality risks

• Extemporaneously compounded intranasal oxytocin for non-obstetric use lacks standardisation

• Chronic use effects on endogenous oxytocin system unknown

• Reproductive safety in first-trimester non-obstetric use not evaluated

• Research-chemical oxytocin products lack sterility and potency assurance

• Potentiated by prostaglandins; combination may cause uterine hyperstimulation

• Cyclopropane anaesthesia: possible maternal bradycardia/hypotension

• Caution in severe pre-eclampsia, cardiovascular disease, cervical surgery

• Not for use in first trimester except for abortion

• WADA: not prohibited

• US DEA: not scheduled

• Reviewed obstetric products are prescription medicines in the cited jurisdictions; historical intranasal lactation-aid products and current scheduling vary by market and must be checked product by product

• Compounded intranasal oxytocin for off-label psychiatric use is not FDA-reviewed

• The obstetric evidence base is substantial but not “complete”; important product-, population-, and outcome-specific gaps remain. Off-label neuropsychiatric efficacy is a major unresolved area

• Intranasal oxytocin dose-response and central penetration are poorly characterised after decades of study

• Sex differences in response not systematically addressed

• Long-term effects of synthetic oxytocin on endogenous oxytocin system unknown

• Conflicting small studies on social cognition have not resolved whether meaningful effects exist in any subpopulation

• Databases and registries: PubMed, FDA Drugs@FDA, DailyMed, WHO EML, ClinicalTrials.gov

• Search terms: Oxytocin, Pitocin, Syntocinon, 50-56-6, labour induction, SOARS-B, postpartum haemorrhage

• Last searched: 2026-08-06

• Inclusion emphasis: regulatory labels, large RCTs, systematic reviews

1. FDA label: Pitocin (oxytocin injection). Drugs@FDA.

2. PubChem CID 439302. https://pubchem.ncbi.nlm.nih.gov/compound/439302

3. DrugBank DB00107. https://go.drugbank.com/drugs/DB00107

4. SOARS-B Trial. NIH. ClinicalTrials.gov NCT01944046.

5. WHO Model List of Essential Medicines. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines

6. StatPearls (NCBI). Oxytocin. PMID 29939625